HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pallone Targets September For House Cosmetics Bill, Hearing

This article was originally published in The Rose Sheet

Executive Summary

With WEN safety issues still weighing on his mind, Congressman Frank Pallone aims to unveil his planned cosmetics legislation in September and push for a public hearing. Safe-cosmetics champion Stacy Malkan and New York Times reporter Eric Lipton joined Pallone August 17 for an NPR panel on “The Battle to Regulate Cosmetics.”

You may also be interested in...



Senate HELP To Hear From Stakeholders In Changed Cosmetics Industry

Since 2012 when a House committee held the last cosmetics hearing, industry generally has warmed to – or resigned itself to – legislative proposals to update the cosmetics regulatory system. However, there is still not consensus on the details among big business, SMEs and consumer advocates, all of which will be represented at the Senate HELP Committee’s witness table.

Pallone Proposes House Companion To PCPSA; Will 2017 Be The Year For Reform?

Like the Personal Care Products Safety Act in the Senate, a bipartisan discussion draft from New Jersey congressmen Frank Pallone and Leonard Lance would require registration and fees from industry while giving FDA ingredient-review duties and recall authority. 2017 could be the year that cosmetics reform legislation goes the distance, but first the Senate will be holding a related hearing September 22.

All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests

In an update on discussions with industry about potential user fees to support FDA's OTC monograph program, CDER officials say "industry and public would suffer" absent new fees.

Related Content

Topics

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel